Literature DB >> 31469630

Autoimmune hemolytic anemia, adverse event to venetoclax.

Carmen Carriles1, Lucía Ordóñez-Fernández2, Aránzazu Arias-Martínez3, Román Menárguez-Blanc4, María Carmen Rosado-María5.   

Abstract

Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31469630     DOI： 10.7399/fh.11230

Source DB:  PubMed          Journal:  Farm Hosp        ISSN： 1130-6343


  3 in total

Review 1.  [Successful treatment with venetoclax and demethylation drugs in one acute myeloid leukemia patient relapsed after cord blood stem cell transplantation: a case report and literature review].

Authors:  J Tong; W Yao; H L Liu; C C Zheng; L Q Geng; X Y Zuo; B L Tang; X Wan; L Zhou; K D Song; X H Zhang; Z M Sun
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

2.  Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?

Authors:  Nizar Abdel-Samad; Rana Sughayar
Journal:  Am J Case Rep       Date:  2021-03-10

Review 3.  Autoimmune Complications in Hematologic Neoplasms.

Authors:  Wilma Barcellini; Juri Alessandro Giannotta; Bruno Fattizzo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.